ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress
31 Juli 2019 - 10:14AM
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage
oncology and immunology focused biopharma company, today
announced that an abstract on varlitinib has been accepted for
poster presentation at the upcoming 2019 European Society for
Medical Oncology (ESMO) Congress in Barcelona, Spain on 27
September - 1 October 2019.
The abstract accepted for poster presentation (Abstract #1311),
titled “A phase I study of varlitinib (VAR; ASLAN001) an oral
pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI
chemotherapy in advanced solid tumors” will be presented by Dr.
Aaron Tan.
Varlitinib is a highly potent pan-HER inhibitor that targets the
human epidermal growth factor receptors HER1, HER2 and HER4. At
ESMO, new data will be presented from a phase 1 study to determine
the safety and maximum tolerated dose (MTD) of varlitinib in
combination with modified irinotecan and infusional 5-fluorouracil
(mFOLFIRI) up to 9 cycles followed by varlitinib monotherapy in
advanced solid tumours. The investigator-initiated trial was
conducted by Dr. Matthew Chau Hsien Ng and supported by ASLAN and
the Singapore National Medical Research Council.
The abstract will be available online at https://www.esmo.org/
on 23 September, 00:05 CEST.
Media and IR contacts
Emma
ThompsonSpurwing CommunicationsTel: +65 6571 2021Email:
ASLAN@spurwingcomms.com |
Robert
UhlWestwicke PartnersTel: +1 858 356 5932Email:
robert.uhl@westwicke.com |
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible,
small molecule pan-HER inhibitor that targets the human epidermal
growth factor receptors HER1, HER2 and HER4. These receptors can be
mutated or overexpressed in many tumours, which can cause excessive
proliferative activity and uncontrolled growth. Therefore, by
inhibiting the activation of the HER receptors, varlitinib could
inhibit proliferation and control tumour growth. Varlitinib has
been granted orphan drug designation in the United States for
gastric cancer and cholangiocarcinoma, a sub-type of biliary tract
cancer, and was awarded orphan drug designation for the treatment
of biliary tract cancer by the Ministry of Food and Drug Safety in
South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a
clinical-stage oncology and immunology focused biopharma company
targeting cancers that are both highly prevalent in Asia and orphan
indications in the United States and Europe. Led by a senior
management team with extensive experience in global and regional
development and commercialisation, ASLAN is headquartered in
Singapore and has offices in Taiwan and China. ASLAN’s clinical
portfolio is comprised of three product candidates which target
validated growth pathways applied to new patient segments, novel
immune checkpoints and novel cancer metabolic pathways. ASLAN’s
partners include Array BioPharma, Bristol-Myers Squibb, Almirall
and CSL. For additional information please visit
www.aslanpharma.com.
Forward looking statements
This release contains forward-looking statements. These
statements are based on the current beliefs and expectations of the
management of ASLAN Pharmaceuticals Limited and/or its affiliates
(the "Company"). These forward-looking statements may include, but
are not limited to, statements regarding the timing, scope,
progress and outcome of the Company’s on-going clinical studies,
the Company’s business strategy, the Company’s plans to develop and
commercialise its product candidates, the safety and efficacy of
the Company’s product candidates, the Company’s plans and expected
timing with respect to regulatory filings and approvals, and the
size and growth potential of the markets for the Company’s product
candidates. These forward-looking statements are based on
management's current assumptions and expectations of future events
and trends, which affect or may affect the Company’s business,
strategy, operations or financial performance, and inherently
involve significant known and unknown risks and uncertainties.
Actual results and the timing of events could differ materially
from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without
limitation the risk factors described in the Company’s US
Securities and Exchange Commission filings and reports (Commission
File No. 001-38475), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2018 filed with the US
Securities and Exchange Commission on April 29,
2019.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024